Risks of Ruxolitinib in STAT1 Gain-of-Function-Associated Severe Fungal Disease

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. 1The Effect of CYP3A4 Inhibition or Induction on the Pharmacokinetics and Pharmacodynamics of Orally Administered Ruxolitinib (INCB018424 Phosphate) in Healthy Volunteers2011 · 116 citations
2. 2<i>STAT1</i> Mutations in Autosomal Dominant Chronic Mucocutaneous Candidiasis2011 · 656 citations
3. 3The Pharmacokinetics, Pharmacodynamics, and Safety of Orally Dosed INCB018424 Phosphate in Healthy Volunteers2011 · 167 citations
4. 4A new alkaloid AM-2282 of Streptomyces origin taxonomy, fermentation, isolation and preliminary characterization.1977 · 677 citations
5. 5Gain-of-function human STAT1 mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis2011 · 805 citations